Biotech Values

[mcbio]

The ovarian data look pretty good on a cursory examination. But note that EXEL has been citing such efficacy metrics as unconfirmed partial responses and “disease control” rates, which have been mentioned from time to time on this board as red flags.

Yes, I know they have been guilty of that type of reporting before. But, I will say that the 32% confirmed response rate per RECIST criteria noted in the Phase 2 ovarian cancer PR sounds pretty objective.

XL184 might yet turn out to be a fine drug; however, I think the recent accolades on various message boards are somewhat premature.

It's still early days for the drug for sure. But, if nothing else, the recent data has caused me to put the stock back on my watch list. I guess I'd add that the change in management probably doesn't hurt either. ; )